LIFE aTyr Pharma

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020.

Conference Call and Webcast Details:

Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT

Domestic:  844-358-9116

International:  209-905-5951

Conference ID:  5176802

Webcast:

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit . 

Contact:
Ashlee Dunston
Investor Relations, aTyr Pharma

EN
06/08/2020

Underlying

LIFEaTyr Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corpora...

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent complet...

August 7, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of...

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Topline results expected in the third quarter of 2025. SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod...

July 22, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russell 3000® Ind...

June 26, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase ...

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and developme...

June 4, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

 aTyr Pharma to Present at Upcoming Investor Conferences

 aTyr Pharma to Present at Upcoming Investor Conferences SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednes...

May 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch